Cardiology Today Current Issue

The following articles appeared in the print edition of Cardiology Today.

Table of Contents

• Clinical use of CV genetic risk information may become common in near future
• FDA advisory committee splits on CV benefit claim for Jardiance
• FDA approves first fully bioresorbable stent for treatment of CAD
• FDA approves monthly injection for evolocumab
• FDA strengthens kidney warnings on Invokana, Farxiga labels
• AHA releases statement on drugs that can cause or worsen HF
• Analysis: Sacubitril/valsartan may prevent many deaths from HF
• ASCOT: Immunoglobulin G antibody levels may be predictive of risk for MI
• Athletic participation risk appears acceptable in properly managed CPVT
• Atrial arrhythmias common after lung transplantation
• CHD rate decreasing in US
• Diabetes increases mortality risk after acute MI
• Donor heart availability may rise with elimination of troponin I test
• Drug-Eluting Scaffold Yields Favorable Safety Results in Patients With PAD
• E-cigarettes increase aortic stiffness, BP in similar manner to tobacco cigarettes
• Fewer patients with hypertension meet SPRINT BP goals
• Genetic score may improve CVD risk prediction in individuals at intermediate risk
• Heterozygous familial hypercholesterolemia hastens risk for CHD
• Higher intake of whole grains may reduce risk for CVD mortality
• Higher stroke mortality rate among middle-aged blacks tied to elevated incidence rate
• Household diesel, kerosene use may raise risk for MI, death
• Men at higher risk for death from sudden cardiac arrest than women
• NHANES: HbA1c increasing among adults with obesity
• Patients with HF after MI at elevated risk for cancer
• President Obama outlines progress, future of Affordable Care Act
• Prevalence of US adults with congenital heart defects increased greatly
• TAVR with Sapien 3 valve yields low mortality, complications at 1 year in high-risk, inoperable patients
• Despite guideline changes, statin use unchanged or lower in patients with diabetes
• EXAMINE: CV events raise mortality risk for patients with diabetes
• New therapies for diabetes: A prescription for reducing CV outcomes Jeff Langford, PharmD, BCPS; Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ Cardiology)
• IBM Watson announces new global collaborative
• NIH awards $55 million to support Precision Medicine Initiative Cohort Program
• Trial Scorecard: ASCOT
• Trial Scorecard: CHANCE
• Trial Scorecard: LEADER
• Trial Scorecard: OASIS
• Trial Scorecard: OPTIMISE
• Trial Scorecard: PARADIGM-HF
• Trial Scorecard: POST 2
• Trial Scorecard: PRESERVE II